tldrdailynews.com logo

Revolution Medicines Opens Early Access for Experimental Pancreatic Cancer Drug After Promising Trial

1 min read
Source: statnews.com
Revolution Medicines Opens Early Access for Experimental Pancreatic Cancer Drug After Promising Trial
Photo: statnews.com
TL;DR

Revolution Medicines has begun shipping its experimental pancreatic cancer drug, daraxonrasib, under an FDA-authorized early-access program after Phase 3 results showed patients lived nearly twice as long as those on standard chemotherapy, fueling high demand ahead of formal FDA approval.

Topics:businesshealth#biotech#daraxonrasib#early-access-program#health#pancreatic-cancer#revolution-medicines
Share this article
  1. Revolution Medicines starts shipping experimental pancreatic cancer drug  statnews.com
  2. Pancreatic cancer is deadly and difficult to treat. A new pill could change that  PBS
  3. How scientists found a weakness in one of the deadliest ‘undruggable’ cancers  The Washington Post
  4. Patients, doctors hail 'revolutionary' new drug for pancreatic cancer  Chicago Sun-Times
  5. Chemo Selection in Metastatic Pancreatic Cancer Continues to Evolve With KRAS-Targeted Therapies on the Horizon  OncLive

Want the full story? Read the original reporting

Read on statnews.com